Medical errors related to inappropriate genetic testing in liver transplant patients

Douglas L. Riegert-Johnson, Daniela MacAya, Timothy W. Hefferon, Lisa Allyn Boardman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Genetic testing of genes that encode proteins expressed by liver hepatocytes (clotting factors, α1-antitrypsin, cytochrome P450 enzymes) is common in clinical practice. These tests use DNA extracted from peripheral blood lymphocytes (PBL) and are based on the assumption that PBL DNA can be used as a surrogate for hepatocyte DNA. However, in individuals who have undergone liver transplantation, hepatocyte DNA is that of the donor while PBL DNA remains that of the recipient. It follows that in liver transplant patients, genetic testing of the recipient's PBL DNA does not provide accurate results for proteins expressed by donor hepatocytes. Therefore, genetic testing of clotting factors, α1-1-antitrypsin, cytochrome P450 enzymes, and other proteins expressed by hepatocytes is unreliable and inappropriate in liver transplant patients (inappropriate genetic testing). A review of the records of 215 consecutive liver transplant patients at our institution identified: one medical error and one near-miss medical error related to inappropriate genetic testing, 14 cases of inappropriate genetic testing, and 21 unnecessary duplicate genetic testing requests. We recommend laboratories performing genetic testing create systems to prevent inappropriate and duplicate genetic testing and that physicians be cognizant of the appropriate indications for genetic testing in liver transplant patients.

Original languageEnglish (US)
Pages (from-to)451-453
Number of pages3
JournalGenetic Testing
Volume11
Issue number4
DOIs
StatePublished - Dec 1 2007

Fingerprint

Medical Errors
Genetic Testing
Transplants
Liver
Hepatocytes
Cytochrome P-450 Enzyme System
DNA
Lymphocytes
Blood Coagulation Factors
Tissue Donors
Proteins
Liver Transplantation
Physicians

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Medical errors related to inappropriate genetic testing in liver transplant patients. / Riegert-Johnson, Douglas L.; MacAya, Daniela; Hefferon, Timothy W.; Boardman, Lisa Allyn.

In: Genetic Testing, Vol. 11, No. 4, 01.12.2007, p. 451-453.

Research output: Contribution to journalArticle

Riegert-Johnson, Douglas L. ; MacAya, Daniela ; Hefferon, Timothy W. ; Boardman, Lisa Allyn. / Medical errors related to inappropriate genetic testing in liver transplant patients. In: Genetic Testing. 2007 ; Vol. 11, No. 4. pp. 451-453.
@article{562be3bad5484d32a6726df133e4dded,
title = "Medical errors related to inappropriate genetic testing in liver transplant patients",
abstract = "Genetic testing of genes that encode proteins expressed by liver hepatocytes (clotting factors, α1-antitrypsin, cytochrome P450 enzymes) is common in clinical practice. These tests use DNA extracted from peripheral blood lymphocytes (PBL) and are based on the assumption that PBL DNA can be used as a surrogate for hepatocyte DNA. However, in individuals who have undergone liver transplantation, hepatocyte DNA is that of the donor while PBL DNA remains that of the recipient. It follows that in liver transplant patients, genetic testing of the recipient's PBL DNA does not provide accurate results for proteins expressed by donor hepatocytes. Therefore, genetic testing of clotting factors, α1-1-antitrypsin, cytochrome P450 enzymes, and other proteins expressed by hepatocytes is unreliable and inappropriate in liver transplant patients (inappropriate genetic testing). A review of the records of 215 consecutive liver transplant patients at our institution identified: one medical error and one near-miss medical error related to inappropriate genetic testing, 14 cases of inappropriate genetic testing, and 21 unnecessary duplicate genetic testing requests. We recommend laboratories performing genetic testing create systems to prevent inappropriate and duplicate genetic testing and that physicians be cognizant of the appropriate indications for genetic testing in liver transplant patients.",
author = "Riegert-Johnson, {Douglas L.} and Daniela MacAya and Hefferon, {Timothy W.} and Boardman, {Lisa Allyn}",
year = "2007",
month = "12",
day = "1",
doi = "10.1089/gte.2007.0052",
language = "English (US)",
volume = "11",
pages = "451--453",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Medical errors related to inappropriate genetic testing in liver transplant patients

AU - Riegert-Johnson, Douglas L.

AU - MacAya, Daniela

AU - Hefferon, Timothy W.

AU - Boardman, Lisa Allyn

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Genetic testing of genes that encode proteins expressed by liver hepatocytes (clotting factors, α1-antitrypsin, cytochrome P450 enzymes) is common in clinical practice. These tests use DNA extracted from peripheral blood lymphocytes (PBL) and are based on the assumption that PBL DNA can be used as a surrogate for hepatocyte DNA. However, in individuals who have undergone liver transplantation, hepatocyte DNA is that of the donor while PBL DNA remains that of the recipient. It follows that in liver transplant patients, genetic testing of the recipient's PBL DNA does not provide accurate results for proteins expressed by donor hepatocytes. Therefore, genetic testing of clotting factors, α1-1-antitrypsin, cytochrome P450 enzymes, and other proteins expressed by hepatocytes is unreliable and inappropriate in liver transplant patients (inappropriate genetic testing). A review of the records of 215 consecutive liver transplant patients at our institution identified: one medical error and one near-miss medical error related to inappropriate genetic testing, 14 cases of inappropriate genetic testing, and 21 unnecessary duplicate genetic testing requests. We recommend laboratories performing genetic testing create systems to prevent inappropriate and duplicate genetic testing and that physicians be cognizant of the appropriate indications for genetic testing in liver transplant patients.

AB - Genetic testing of genes that encode proteins expressed by liver hepatocytes (clotting factors, α1-antitrypsin, cytochrome P450 enzymes) is common in clinical practice. These tests use DNA extracted from peripheral blood lymphocytes (PBL) and are based on the assumption that PBL DNA can be used as a surrogate for hepatocyte DNA. However, in individuals who have undergone liver transplantation, hepatocyte DNA is that of the donor while PBL DNA remains that of the recipient. It follows that in liver transplant patients, genetic testing of the recipient's PBL DNA does not provide accurate results for proteins expressed by donor hepatocytes. Therefore, genetic testing of clotting factors, α1-1-antitrypsin, cytochrome P450 enzymes, and other proteins expressed by hepatocytes is unreliable and inappropriate in liver transplant patients (inappropriate genetic testing). A review of the records of 215 consecutive liver transplant patients at our institution identified: one medical error and one near-miss medical error related to inappropriate genetic testing, 14 cases of inappropriate genetic testing, and 21 unnecessary duplicate genetic testing requests. We recommend laboratories performing genetic testing create systems to prevent inappropriate and duplicate genetic testing and that physicians be cognizant of the appropriate indications for genetic testing in liver transplant patients.

UR - http://www.scopus.com/inward/record.url?scp=38149059894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149059894&partnerID=8YFLogxK

U2 - 10.1089/gte.2007.0052

DO - 10.1089/gte.2007.0052

M3 - Article

C2 - 18294063

AN - SCOPUS:38149059894

VL - 11

SP - 451

EP - 453

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 4

ER -